Overview

The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic HCV Genotype 2 Infection

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To determine the P1101 PK profile at the single dose of 400 μg.
Phase:
Phase 1
Details
Lead Sponsor:
PharmaEssentia
Treatments:
Ribavirin